Pharmacological treatment of neurogenic detrusor hyperactivity: Intradetrusor botulinum toxin A injections;Traitement pharmacologique de l'hyperactivité détrusorienne neurologique: Injections intra-détrusoriennes de toxine botulique A

Progres en Urologie

Volumn 17, Issue 3, 2007, Pages 568-575

  Karsenty, G ^a   Corcos, J ^a   Schurch, B ^a   Ruffion, A ^a   Chartier Kastler, E ^a  

^a NONE

Author keywords

Benign prostatic hyperplasia; Botulinum toxin; Incontinence; Neurogenic bladder; Urinary retention

Indexed keywords

EID: 34250838021     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(07)92370-2     Document Type: Article

References (53)

1. Lamanna C: The most poisonous poison. Science. 130: 763-72, 1959.
2. Johnson EA: Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol. 53: 551-75, 1999.
3. Cherington M: Botulism: update and review. Semin Neurol. 24: 155-63. 2004.
4. Hallen M: Effect of botulinum toxin at the neuromuscular junction, in Brin F, Hallet M and Jankovic J: Scientific and therapeutic aspect of botulinum toxin, Lippincott Williams and Wilkins, 1999, pp 167-170.
5. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R and Chapman ER: SV2 is the protein receptor for botulinum neurotoxin A. Science. 312: 592-6, 2006.
6. MacKenzie I, Burnstock G and Dolly JO: The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropineresistant autonomic neuromuscular transmission. Neuroscicnce. 7: 997-1006, 1982.
7. Welch MJ, Purkiss JR and Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 38: 245-58, 2000.
8. de Paiva A. Meunier FA. Molgo J, Aoki KR and Dolly JO: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 96; 3200-5, 1999.
9. Setler PE: Therapeutic use of botulinum toxins: background and history. Clin J Pain. 18: 5119-24, 2002.
10. Brooks VB: Motor nerve filament block produced by botulinum toxin. Science. 117;334-39, 1953.
11. Scott AB, Rosenbaum A and Collins CC: Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 12; 924-7, 1973.
12. Scott AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. 17: 21-5, 1980.
13. Jankovic: Botulinum toxin in clinical practice, J Neurol Neurosurg Psychiatry. 75;951-7, 2004.
14. Apostolidis A, Popat R. Yiangou Y, Cockayne D. Ford AP, Davis JB, Dasgupta P. Fowler CJ and Anand P: Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 174: 977-82; discussion 982-3, 2005.
15. Khera M, Somogyi GT, Kiss S, Boone TB and Smith CP: Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int. 45: 987-93, 2004.
16. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB and Chancellor MB: Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 64: 871-5; discussion 875, 2004.
17. Aoki KR: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 26: 785-93, 2005.
18. Dykstra DD, Sidi AA, Scott AB, Pagel JM and Goldish GD: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 139: 919-22, 1988.
19. Schuren B. Stohrer M, Kramer G, Schmid DM, Gaul G and Hauri D: BotuIinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 164: 692-7, 2000.
20. Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS and Bales GT: Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology. 63: 1071-5, 2004.
21. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G and Albanese A: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 62: 259-64; discussion 264-5, 2003.
22. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B and Dawes M: Levels of evidence and grades of recommandation., 2001.
23. Giannantoni A, Di Stasi SM, Nardicchi V, Zucchi A, Macchioni L, Bini V, Goracci G and Porena M: Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol. 175: 2341-4, 2006.
24. Kuo HC: Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 66: 94-8, 2005.
25. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N and Chancellor MB: Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 65: 37-41, 2005.
26. Karsenty G, Boy S, Reitz A. Knapp PA, Bardot P. Tournebise H, Fortanier C. Loundou A, Bladou F, Serment G et al. : Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)- A prospective randomized study to compare 30 vs. 10 injection sites. Neurourol Urodyn. 24: p 401-598, abstract No93, 2005.
27. Karsenty G, Elzayat E, Delapparent T, St.Denis D, Lemieux MC und Corcus J: Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol, In Press.
28. De Laet K and Wyndaele JJ: Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord. 43: 397-9, 2005.
29. Kuo HC: Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology. 61: 550-4, 2003.
30. Reitz A and Schurch B: Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol. 171: 804; discussion 804-5, 2004.
31. Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdorfer H, Gocking K, Madersbacher H, Schumacher S et al.: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 45: 510-5, 2004.
32. Bagi P and Biering-Sorensen F: Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol. 38: 495-8, 2004.
33. Hajebrahimi S, Altaweel W, Cadoret J, Cohen E and Corcos J: Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol. 12: 2543-6, 2005.
34. Kessler TM, Danuser H, Schumacher M. Studcr UE and Burkhard FC: Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity',' Ncurourol Urodyn. 24: 231-6, 2005.
35. Schuren B, de Seze M, Denys P. Chartier-Kastler E. Haab F, Everaert K. Plante P, Perrouin-Verbe B, Kumar C, Fraczek S et al.: Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 174: 196-200, 2005.
36. Popat R, Apostolidis A. Kalsi V. Gonzales G, Fowler CJ and Dasgupta P: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 174: 984-9, 2005.
37. Kuo HC: Urodynamic evidence of effectiveness of bolulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology. 63: 868-72, 2004.
38. Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, Shah PJ and Malone-Lee J: Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 174: 1873-7; discussion 1877, 2005.
39. Klaphajone J, Kitisomprayoonkul W and Sriplakit S: Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil. 86: 2114-8, 2005.
40. Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A and Grise P: What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int. 97: 1030-4, 2006.
41. Schulte-Baukloh H, Schobert J, Stolze T, Sturzebecher B, Weiss C and Knispel HH: Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn. 25: 110-5, 2006.
42. Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Sturzebecher B, Miller K and Knispel HH: Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol. 48: 984-90; discussion 990, 2005.
43. Grosse J, Kramer G and Stohrer M: Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 47: 653-9, 2005.
44. Karsenty G, Reitz A, Lindemann G, Boy S and Schurch B: Persistance of the therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology, In press.
45. Pistolesi D, Selli C, Rossi B and Stampacchia G: Botulinum toxin type B for type A resistant bladder spasticity. J Urol. 171: 802-3, 2004.
46. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E and Porena M: Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 172: 240-3, 2004.
47. Schulte-Baukloh H, Michael T, Sturzebecher B and Knispel HH: Botulinuma toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. 44: 139-43, 2003.
48. Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L and Bauer SB: Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol. 171: 845-8; discussion 848, 2004.
49. Altaweel W, Jednack R, Bilodeau C and Corcos J: Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol. 175: 1102-5, 2006.
50. Schurch B and Corcos J : Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 15: 264-7, 2005.
51. Naumann M and Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 20: 981-90, 2004.
52. Haferkamp A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G, Schumacher S, Bastian PJ, Buttner R, Muller SC et al.: Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol. 46: 784-91, 2004.
53. Schurch B, Schmid DM and Stohrer M: Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 342: 665, 2000.